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 Abstract  
 
The production of very low density lipoprotein and high density lipoprotein particles by 
the liver is a tightly regulated process, which begins with synthesis and assembly of core protein 
components in the rough endoplasmic reticulum. Factors influencing the production and 
metabolism of these particles are of immediate medical relevance, as their malfunction or 
hyperactivity can lead to an assortment of disease states. Hepatic lipase is a secreted liver 
enzyme, with many previously described roles in the metabolism and clearance of both high and 
low density lipoproteins. Increased production and assembly of this enzyme is an indicator of 
metabolic dysfunction, while its absence or insufficiency leads to pre-mature atherosclerosis and 
death. The present study shows that this enzyme’s role in lipoprotein metabolism is not confined 
to the degradation and clearance of these particles after they have been secreted. Experiments 
using co-immunoprecipitation targeted at hepatic lipase demonstrate that this protein interacts 
with ApoA1 and ApoB100, the core protein components of HDL and VLDL respectively, at the 
ER level in hepatocytes, as part of an enormous multi-subunit protein complex. This interaction 
with ApoA1 leads to decreased competence of hepatocytes to secrete HDL, which confers a pro-
atherogenic phenotype. Analysis of ER to Golgi VLDL transport vesicles, produced with a cell-
free in vitro budding assay, has revealed that hepatic lipase is co-secreted between these 
compartments with immature VLDL particles. Further analysis of cytosol isolated from 
hepatocytes demonstrates an interaction between hepatic lipase and the LDL-receptor related 
protein in a post-Golgi vesicle; the significance of which will be investigated in future studies.  
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Chapter 1: Literature Review and Aims 
 
Introduction 
 
The aims of this study are twofold; identify the role played by hepatic lipase in ApoA1 
trafficking, particularly at the level of the endoplasmic reticulum (ER), and also to determine the 
relationship between VLDL secretion and hepatic lipase secretion. This information will aid in 
the development of drugs aimed at increasing the ability of hepatocytes to secrete ApoA1/HDL. 
Increased ApoA1/HDL serves to increase reverse cholesterol transport and to prevent LDL 
oxidation, both of which in turn will decrease the risk for developing atherosclerosis. The 
process of ApoA1 retention by pre-folded hepatic lipase can be targeted at the level of 
transcription by anti-sense oligonucleotides, which target siRNA encoding the hepatic lipase 
gene, or at the post-translational level by introducing some factor that disrupts the association 
between these two proteins.  
VLDL trafficking between the ER and cis-Golgi is a tightly regulated process, the rate of 
which ultimately limits the secretion of VLDL. Enhance VLDL secretion is an independent risk 
factor for developing atherosclerosis, which is exacerbated in different forms of metabolic 
disturbances, such as insulin resistance. Thus, identification of factors that diminish or enhance 
the rate at which ER to Golgi movement occurs are of utmost importance to developing 
treatments directed at modulating VLDL secretion. This study aims to lay ground work for future 
studies aimed at elucidating the means by which hepatic lipase alters VLDL trafficking and 
secretion in hepatocytes. 
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Early Observations 
 
Human plasma typically contains little to no lipolytic activity. Early observations by 
Hahn in 1943 demonstrated that addition of heparin to lipemic human serum would rapidly 
induce lipid hydrolysis, which led to the eventual discovery of lipoprotein lipase [1]. While this 
was an exciting development in lipid metabolism, it was well known that lipoprotein lipase 
activity alone could not account for 100% of the lipolysis induced in human serum upon heparin 
injection. Some twenty years after the description of lipoprotein lipase, Sinderman et al, 
described the presence of heparin inducible lipase of hepatic origin [2]. A clear distinction 
between the two proteins was drawn by need for ApoCII as a cofactor. Lipoprotein lipase 
demonstrated no lipolytic activity in 1 molar NaCl, due to the fact that these conditions disrupt 
interaction with ApoCII, while hepatic lipase retained full activity [3, 4]. Clinically, this is used 
to assess risk for cardiovascular disease. NaCl sensitive lipolytic activity is subtracted from total 
lipolytic activity to indirectly measure hepatic lipase activity, which is directly related to 
cardiovascular disease [5]. 
 
Overview 
 
Hepatic lipase is a lipolytic enzyme produced in the liver, adrenal cortex, and 
macrophages [6, 7]. The production of this enzyme by steroidogenic organs such as the ovaries 
and testis, in addition to those previously listed, is still a subject of debate. The mature enzyme is 
found in two inactive pools within the body; anchored to heparan sulfate proteoglycans (HSPG) 
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of hepatocytes and endothelial cells, as well as bound to ApoA1 and ApoA2 containing HDL, 
which are responsible for its release from the surface of hepatic sinusoids [8, 9].  
The enzyme shows dual functionality as an A1 phospholipase as well as triglyceride 
lipase. It has been demonstrated that the enrichment of HDL particles with triglycerides (HDL2) 
as well as anionic lipids regulates the lipolysis of VLDL triglycerides by hepatic lipase [8]. This 
enzyme is also responsible for the maturation of HDL2 to type three high density lipoproteins, 
and for the transformation of intermediate density lipoproteins (IDL) to low density lipoproteins 
(LDL). The initial discovery of this function originates from clinical cases, in which patients 
with a LIPC loss of function mutation presented with elevated concentrations HDL2 as well as 
elevated IDL [10]. Both of the previously mentioned functions represent the latter steps in the 
degradation processes of the respective lipoprotein particles. Thus, the catalytic activity of 
hepatic lipase plays a large role in determining lipoprotein subtype profile, which used clinically 
to assess cardiovascular disease risk.  
In cases of insulin resistance, the over activity and expression of hepatic lipase has been 
observed, and implicated in the formation of small dense LDL, which are known to promote 
atherosclerosis [11, 12]. Another feature of insulin resistance is an increase in the secretion of 
VLDL particles by the liver [13]. While the two factors independently increase risk for 
atherosclerosis, no study to date has described how the two pathophysiological states relate to 
each other, or if hepatic lipase expression has an impact on the trafficking or secretion of VLDL 
from hepatocytes in the insulin resistant state.  
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In addition to the lipolytic function for which hepatic lipase was named, a likewise 
important ligand binding function was later described. This function aids in the uptake of whole 
low density lipoprotein particles, in addition to the selective uptake of cholesterol esters from 
high density lipoproteins [14]. The protein’s role in HDL-c uptake mediates a reduction in levels 
of HDL-c, which is observed to have an inverse relationship with blood triglycerides in the 
diabetic dyslipidemia [11]. Lowered serum HDL-c levels and elevated triglycerides have been 
implicated as a risk for cardiovascular disease [15]. Further studies revealed that the uptake of 
these whole LDL particles is due to a direct interaction between hepatic lipase and ApoB100, 
which is the core protein component of LDL [16]. The ligand binding or “bridging” function of 
hepatic lipase is dependent on the presence of heparan sulfate proteoglycans, and is further 
mediated by LDL receptor related protein (LRP), or the LDL receptor as a separate pathway [17-
19].  
This process is also sensitive to the protein composition of lipoprotein particles, which changes throughout 
their maturation. For cells up taking these triglyceride rich remnant particles by LRP mediated endocytosis, 
ApoE is a required cofactor, in addition to the cell surface proteoglycans [17]. In the fasted state, the 
majority of ApoE is confined to HDL particles. The transfer of ApoE to LDL occurs in the post-prandial 
hyperlipidemic state when triglyceride rich VLDL is being produced by the liver. While ApoE is a 
necessary cofactor for the endocytosis of LDL particles and HDL cholesterol ester uptake, its presence on 
HDL inactivates the catalytic activity of hepatic lipase by reducing the ability of HDL particles to remove 
the enzyme from cell surface HSPG. Simultaneous to the exchange of proteins in this lipemic state, 
cholesterol ester transfer protein mediates the exchange of cholesterol esters on HDL particles for 
triglycerides present on VLDL or IDL particles. Collectively, these processes mediate triglyceride 
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enrichment of HDL particles, which can be used later as an energy substrate; along with the cholesterol 
enrichment of ApoB containing particles (LDL), which are then taken up by and degraded in the liver with 
the aid of hepatic lipase’s ligand binding function.  
It has been observed that the expression of scavenger receptor-B1 and hepatic lipase are 
regulated similarly in the liver as well as in steroidogenic organs, and that their expression is 
inversely related to cellular cholesterol content [20]. These two proteins act in concert to 
facilitate cellular cholesterol ester uptake in perfused rat livers [21]. Studies with hepatic 
lipase/ApoA1 double knockout mice have shown that the female knockout mice produce a lesser 
amount of progesterone when compared to non-transgenic littermates, and that this is due to a 
lack of available substrate in steroidogenic tissues [22]. Taken together, these studies 
demonstrate the current understanding of role this enzyme plays in the sequestration of 
cholesterol by different cell types, along with the role played by SR-B1 in assisting with this 
process.  
Factors which mediate the maturation of hepatic lipase in the endoplasmic reticulum (ER) 
have been well studied. Doolittle et al, have shown in Chinese hamster ovary cells that the rate 
limiting step in the enzyme’s secretion is proper folding at the ER level, and that this process 
entails the formation of a myriad of complexes of differing composition, some of which include 
the chaperones calnexin and lipase maturation factor 1 [23, 24]. Maturation of hepatic lipase 
takes hours, as opposed to minutes in the case of its close genetic cousin lipoprotein lipase, and 
as much as half of the initially translated enzyme is degraded by a proteasome mediated 
pathway, which has yet to be described. In addition to this, the mechanisms directly regulating 
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this enzyme’s secretion, and the components with which it secretes from the ER in hepatocytes 
has not been described. 
 
Transgenic studies 
 
While the ligand binding function of hepatic lipase has been deemed “anti-atherogenic” 
by some transgenic studies due to its role in facilitating LDL uptake [25, 26], other studies using 
tissue specific expression in macrophages showed that this same role increased the formation of 
atherosclerotic plaques [27]. When compared to catalytically inactive variants of hepatic lipase, 
Gonzalez-Navarro, H. et al, were able to demonstrate that the ligand binding function decreased 
the formation of aortic leasions in ApoE knockout mice, which are used as an animal model for 
atherosclerosis. Despite a similar reduction in ApoB containing lipoprotiens between groups 
expressing the catalytically active and catalytically inactive varriants of the enzyme, aortic lesion 
formation was actually increased in mice expressing the catalytically active form of hepatic 
lipase, when compared to the control group expressing neither varriant. These studies show that 
the bridging function of hepatic lipase is essential to the clearance of ApoB100 containing 
lipoprotien remnants by the liver and that this can occur independent of its catalytic function. 
However, the same ligand binding function may also aid in the uptake of small dense LDL 
particles by artery dwelling macrophages, and contribute to the pathogenesis of atherosclerosis. 
In a recent study performed by Escola-Gil et al., it was shown that mice lacking hepatic 
lipase or endothelial lipase demonstrate an increase in macrophage to feces reverse cholesterol 
transport, as well as HDL anti-oxidant properties [28]. RCT and prevention of LDL oxidation are 
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two of the primary reasons why HDL is considered “good cholesterol”. Both processes directly 
inhibit foam cell formation and growth, which describes the process by which macrophages 
accumulate cholesterol within fatty plaques and occlude the lumen of arteries [29]. The oxidation 
of LDL molecules leads to their recognition by the CD36 and SR-A1 receptors present on 
macrophages. As the accumulation of cholesterol by these cells proceeds, changes in gene 
expression occur in an effort to restore homeostasis. Cholesterol efflux mediated by ApoA1 
containing HDL is increased to restore balance. The aforementioned study showed that when 
macrophages containing tritium labeled cholesterol were injected into mice lacking either lipase, 
they were able to excrete more of the radioactive tritium through their feces as bile when 
compared to the wild type control. Furthermore, HDL particles isolated from either group of 
knockout mice showed an increased ability to protect LDL molecules from oxidation in vitro. 
This characteristic was attributed to increased levels of ApoA1 in HDL particles from both 
knockout groups. These observations indicate that hepatic lipase may exert a negative impact on 
the ability of macrophages to secrete HDL, and that in the absence of hepatic lipase, LDL 
particles may less prone to oxidation. 
Mice lacking hepatic lipase have also demonstrated protection against hepatic steatosis as 
well as obesity in response to a high fat diet [30]. Taken with the observation that impaired 
secretion of VLDL leads to the development of hepatic steatosis [31], this indicates that hepatic 
lipase may play some role in down regulating VLDL secretion, or that its absence can be 
compensated for in mice. Furthermore, recent studies using metabolic profiling as well as in vitro 
and in vivo assessments of gene expression have demonstrated that VLDL triglyceride hydrolysis 
by hepatic lipase selectively activates the nuclear receptor PPARδ [32]. This receptor is known 
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to induce production of adipocyte differentiation related protein, which is associated with lipid 
droplet formation as well as adipocyte proliferation and enlargement. This is paralleled by 
observations from the previously mentioned study in hepatic lipase knock-out mice, which 
demonstrated reduced macrophage infiltration of peritoneal fat. Based on this observation it was 
proposed that free fatty acids produced by hepatic lipase activity in these fat dwelling 
macrophages contributes to worsening inflammation and increased substrate availability for 
triglyceride storage by adipocytes.  
While many studies have implicated the significance of the catalytic and “bridging” 
functions of hepatic lipase in lipoprotein metabolism outside of the cell, recent studies have 
called into question the role played by this protein inside of the cell. Yao’s group has 
demonstrated that hepatocytes from LIPC null mice (lacking hepatic lipase) transfected with 
human hepatic lipase secrete less ApoA1 when compared to control [33]. This study also 
analyzed the impact of transfection with mouse hepatic lipase, which lacks the C-terminal 
heparin binding domain.  A similar decrease in ApoA1 secretion was observed in this group, and 
an increase in unfolded hepatic lipase residing in the ER, relative to human hepatic lipase 
transfection, was also observed. This indicates that the C-terminal heparin binding domain, along 
with the N-terminal heparin binding domain present in both species, may play a role in the 
proper folding and secretion of this enzyme.  
The study proposed that the observed impact of this enzyme on ApoA1 secretion may 
occur as a result of direct interaction between ApoA1 and hepatic lipase, or alternatively by 
changes in gene expression due to the activity of hepatic lipase. The observation that the 
selective hydrolysis of VLDL triglyceride by hepatic lipase leads to PPARδ activation indicates 
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that changes in gene expression are not entirely out of the question. Furthermore, recent in vitro 
studies have suggested that hepatic lipase becomes active in the ER, leading to decreased 
availability of triglycerides, which are necessary for secretion of VLDL [34]. However, 
aforementioned studies into the maturation of hepatic lipase have indicate that the protein is 
rapidly secreted from the ER upon dimerization, which is also when the enzyme gains catalytic 
activity [24]. The rate limiting step in the secretion of VLDL from the liver is movement from 
the ER to the cis-Golgi, in a specialized VLDL transport vesicle, or VTV [35]. 
Aims 
 
Aim 1: The primary aim of the present study is to identify whether or not any 
interaction between hepatic lipase and ApoA1 exists at the ER level. The majority of ApoA1 
found in circulation originates from the liver, and thus any factor affecting the proper secretion 
of this crucial, anti-atherogenic lipoprotein from hepatocytes warrants investigation. This was 
accomplished using co-immunoprecipitation, silver staining and western blot analysis. 
Aim 2: The secondary aim of this study is to assess the relationship between hepatic 
lipase and VLDL movement from the ER to the cis-Golgi. ApoB100 is the core component of 
VLDL molecules, and our lab has extensively studied the mechanisms related to the secretion of 
these pro-atherogenic particles. This was analyzed with an in vitro budding assay, TCA 
precipitation of budding fractions, co-immunoprecipitation, silver staining, and western blot 
analysis. 
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Chapter 2: Materials and Methods 
 
SDS-PAGE and western blot analysis  
  
Protein concentration was determined by the Bradford method [36]. Proteins were 
separated by SDS-PAGE and then transferred to nitrocellulose membranes (Bio-Rad). Western 
blot protein analysis was accomplished with ECL western blot reagent (GE Healthcare), and 
autoradiography film (MIDSCI, St. Louis, MO). Secondary antibodies were conjugated to 
horseradish peroxidase (Santa Cruz Biotechnology), with luminol as the light producing 
substrate in ECL. 
Co-immunoprecipitation  
 
Samples containing 500 μg protein were incubated with rabbit anti-hepatic lipase 
antibodies for 4 hours at 4°C while rotating (Santa Cruz Biotechnology). ER samples were 
incubated in 2% triton-X for 10 minutes at 4°C to solubilize membranes. After 4 hours 
incubation, secondary antibodies conjugated to agarose beads were added (Santa Cruz 
Biotechnology). After the addition of secondary antibodies targeting the FC region of rabbit 
antibodies, the samples were incubated at 4°C over night while rotating.  
The formed immune complexes were washed 10 times with cold PBS. Samples were 
subsequently boiled and vortexed to release their contents. The supernatant was then separated 
by SDS-PAGE. The same procedure was performed simultaneously with anti-IgG primary 
antibodies as a control. 
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Preparation of Hepatic Cytosol 
  
Hepatocytes were washed thoroughly in Krebs buffer, and then cytosol buffer (25 mM 
HEPES, 125mM KCl, 2.5mM MgCl2, .5 mM DTT, protease inhibitors, pH 7.2). Cells were 
homogenized using a Parr bomb at 1100 psi for 40 minutes. Samples were then centrifuged at 
40,000 RPM for 95 minutes (Beckman rotor, 70.1, Ti). The supernatant was collected at cytosol. 
Samples were then dialyzed with fresh cytosol buffer, concentrated with a Centricon 
filter, and ultrafiltration membrane with a 10 kDa cutoff (Millipore, Billerica, MA). Final 
concentration of cytosol samples was determined to be 19 mg/mL by Bradford method. 
Preparation of ER samples  
 
Hepatocytes were homogenized in .25M sucrose in 10 mM HEPES, 50 mM EDTA, and 
protease inhibitor, using a Parr bomb at 1100 psi for 40 minutes. ER, cis-Golgi, and trans-Golgi 
fractions were isolated by step gradient ultracentrifugation  [35]. This step was repeated to 
ensure purity. 
 
In Vitro ER Budding 
 
VTV generation was induced by incubating intact rat liver ER membranes (500μg 
protein) with rat liver cytosol (1mg protein) and an ATP generating system 5 mM Mg2+, 0.5 
mM Ca2+, 5 mM DTT, 1 mM GTP, 1 mM E600. Final volume was adjusted to 500 μl with 
transport buffer, (30 mM HEPES, 250 mM sucrose, 2.5 mM MgOAc, 30 mM KCl; pH 7.2) [36]. 
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Termination of the reaction was achieved by placing the tubes on ice. The mixture was overlaid 
on a continuous sucrose gradient, .2 molar to 2.1 molar, and centrifuged with a Beckman rotor 
SW41 at 25,900 rpm for 2 h at 4 °C [36]. 500 μl aliquots were separated from the continuous 
gradient and stored at -20°C until needed. 
TCA Precipitation 
 
150 μl of each 500 μl fraction from the sucrose gradient used to resolve the VTV budding 
assay were incubated with 150 μl of 30% trichloroacetic acid (TCA) at 4°C for 30 minutes, after 
thorough vortexing. Samples were then pelleted by 15 minute centrifugation at 13400 RPM in a 
bench top centrifuge. The supernatant was discarded. Cold (-20°C) acetone was added to the 
pellet, vortexed thoroughly, and incubated at 4°C for 30 minutes. Samples were then pelleted by 
15 minute centrifugation at 13400 RPM in a bench top centrifuge. The supernatant was 
discarded. 15 μl of .5 normal NaOH was added to the pellet and incubated at room temperature 
for 10 minutes to neutralize the excess trichloroacetic acid. Samples were stored at -20°C until 
use.  
Silver Staining 
 
After immunoprecipitation was performed as described previously, samples were 
resolved by 4%-20% SDS-PAGE. To prevent diffusion of proteins, the gel was incubated in 200 
ml fixing buffer (10% accetic acid v/v, 30% ethanol v/v in d.i. H20) while rocking at room 
temperature for 1 hour. To complete fixing, the gel was transferred to incubation buffer (.83 M 
sodium acetate, 30% ethanol v/v, 8 mM sodium thiosulfate, .5% v/v glutaraldehyde) and left 
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rocking over night at room temperature. The gel was washed three times in d.i. water to remove 
excess fixing agents. Silvering was accomplished by incubating the gel in silvering agent (0.02% 
v/v formaldehyde, 12 mM silver nitrate) for 20 minutes while rocking at room temperature in the 
absence of light. Developing of the silver stained bands was accomplished by repetitive 
incubation/washing with developing buffer (236 mM sodium carbonate, .01% v/v 
formaldehyde), until bands were adequately visible. Termination of the reaction was 
accomplished with rinsing and incubation in 1% m/v glycine. 
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Chapter 3: Results and Discussion 
 
To identify protein complexes that impact the secretion of lipoproteins in the 
endoplasmic reticulum of rat hepatocytes, immunoprecipitation was performed using primary 
antibodies against hepatic lipase, and resolved by SDS-PAGE. Based on the presence of a bands 
with an apparent molecular mass at 100kDa and 250kDa in the non-boiled sample, and bands at 
approximately 28kDa and 53kDa in the boiled sample of our silver staining procedure, seen in 
Figure 1, further immunoprecipitation and western blot analysis was performed to determine 
definitively if hepatic lipase forms complexes with ApoA1, ApoB100, or other lipoprotein 
components at the ER level. Analysis of cytosolic samples as well as VTV budding samples was 
performed later in order to determine the paradigm responsible for hepatic lipase secretion. 
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Silver Staining 
 
 
Figure 1 Silver staining was performed on ER co-immunoprecipitation samples, with primary 
anti-hepatic lipase antibodies. Boiling was performed for 5 minutes at 100°C prior to SDS-
PAGE for indicated samples. Samples were resolved by 4% to 20% gradient SDS-PAGE.  
The lane containing boiled samples is representative of separated components belonging 
to various ER complexes in which hepatic lipase is involved. The non-boiled sample was not 
able to resolve the complex, due to its excessive mass. The IgG heavy chain and light chain are 
observed at 50kDa and 25kDa, respectively, are present in both samples.  
 Boiled   Non-Boiled  Marker 
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ApoA1 
 
To confirm the identity of the 28 kDa band in the boiled samples of Figure 1 as ApoA1, 
immunoprecipitation of ER samples was performed in the same fashion, resolved by SDS-
PAGE, transferred to nitrocellulose membranes, and analyzed by western blot. 
 
Figure 2 Western blot of ApoA1 from anti-hepatic lipase immunoprecipitation samples, from rat 
hepatic cytosol and ER. ER control was solubilized in 2% triton-X detergent prior to SDS-
PAGE. HL denotes experimental observation using primary anti-hepatic lipase. IgG denotes 
control using primary anti-IgG. Samples were resolved on 12% SDS-PAGE.  
To verify complex formation, analysis of boiled and non-boiled ER samples was 
performed with and without the presence of heparin. Heparin at a concentration of 100 μg/μl has 
been shown to block the association of hepatic lipase with LRP [19]. Based on this, incubation of 
ER samples with this concentration of heparin was used to investigate complex formation while 
blocking the N and C terminal heparin binding domains of hepatic lipase. Previous studies have 
demonstrated that mice expressing hepatic lipase deficient in the heparin binding domains 
present with low concentrations of ApoA1 HDL [37]. Thus, blocking these domains with heparin 
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was employed in this study to analyze the how this affects the interaction of hepatic lipase with 
ApoA1, which we have hypothesized mediates previously observed reductions in ApoA1 
secretion. 
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a) 
b) 
 
Figure 3  Western blot of a) ApoA1 b) hepatic lipase, from hepatic ER samples resolved by 
4-20% gradient SDS-PAGE. All lanes contain 42μg total protein. Membranes were solubilized in 
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2% triton-X detergent. Boiled ER was kept at 4°C and boiled for 5 minutes at 100°C prior to 
SDS-PAGE. All heparin and non-heparin samples were incubated at 4°C for one hour after 
heparin was added to the positive samples, and subsequently incubated at 37°C for one hour. 
Samples were either boiled for 5 minutes prior to SDS-PAGE indicated by “boiled”, or loaded 
after incubation at 37°C, as indicated by “non-boiled”. Boiled ER (c) was incubated at described 
for heparin/non-heparin containing samples and boiled as described prior to SDS-PAGE to 
control for artifacts created by the incubation process. 
  
20 
 
ApoB100 
 
In order to confirm the suspected identity of the 250kDa band as ApoB100 in the boiled 
sample of our silver staining experiment Figure 1, western blot analysis was performed on ER 
immunoprecipitation samples. Further analysis with immunoprecipitation experiments were 
performed to determine if interaction between these proteins occurs within vesicles present in the 
cytosol bound for fusion with the Golgi, or cell membrane. 
 
Figure 4 Western blot for ApoB100 originating from anti-hepatic lipase co-immunoprecipitation 
samples from rat hepatic cytosol. IgG denotes the control using primary anti-IgG antibodies.  
The middle lane labeled HL denotes the experimental observation with primary anti-hepatic 
lipase antibodies. To the right is a cytosolic sample added as a control, containing 40 μg total 
protein. Samples were resolved on 12% SDS-PAGE. Bands at 250kDa represent the truncated 
ApoB48 isoform, while the band at a greater molecular mass denotes the full length 515kDa 
ApoB100 band. Both transcripts are produced in rat hepatocytes [38]. 
21 
 
 
Figure 5 Western blot of ApoB100 from anti-hepatic lipase immunoprecipitation samples, from 
rat hepatic ER. IgG denotes control using primary anti-IgG. The middle lane labeled HL denotes 
the experimental observation with primary anti-hepatic lipase antibodies. ER control was 
solubilized in 2% triton-X detergent prior to immuno-precipitation. Samples were resolved on 
12% SDS-PAGE. Bands at 250kDa represent the truncated ApoB48 isoform, while the band at a 
greater molecular mass denotes the full length 515kDa ApoB100 band. Both transcripts are 
produced in rat hepatocytes [38].  
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Hepatic Lipase is Present in VTVs 
 
TCA precipitation was performed on VTV budding fractions in order to determine what 
paradigm mediates the secretion of hepatic lipase from the endoplasmic reticulum. The COPII 
complex mediates the selective movement of nascent proteins from the endoplasmic reticulum to 
the cis-Golgi [39]. This COPII coat induces the formation of protein transport vesicles, or PTVs, 
which deliver nascent protein cargo to the cis-Golgi. Our lab has previously demonstrated that 
ApoB100, the core component of VLDL particles, is transported between these cellular 
compartments in a specialized VLDL transport vesicle, or the VTV. This is vesicle 
biochemically distinct from the PTV in terms of protein composition, size, and density [35]. This 
process is of particular significance, because it is the rate limiting step in VLDL secretion. While 
the process of VTV formation is dependent on components of the COPII complex, there are 
distinct differences in the requirements for budding of each vesicle.  
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a) 
 
b) 
 
Figure 6 Western blots of a) hepatic lipase and b) LRP, from the four low density fractions of 
VTV budding assay continuous sucrose gradient, F1 being the lowest density. Samples were 
resolved on 12% SDS-PAGE after TCA precipitation. A cytosol samples was included as control 
for the efficacy of LRP identification. 
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LDL Receptor Related Protein 
 
 
Figure 7 Western blot of LRP originating from anti-hepatic lipase co-immunoprecipitation 
samples from rat hepatic cytosol. IgG denotes the control using primary anti-IgG antibodies.  
The middle lane labeled HL denotes the experimental observation with primary anti-hepatic 
lipase antibodies. To the right is a cytosol sample added as a control, containing 40 μg total 
protein. Samples were resolved on 12% SDS-PAGE. 
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ApoAIV 
 
 
Figure 8 Western blot of ApoAIV originating from anti-hepatic lipase co-immunoprecipitation 
samples from rat hepatic cytosol. IgG denotes the control using primary anti-IgG antibodies.  
The middle lane labeled HL denotes the experimental observation with primary anti-hepatic 
lipase antibodies. To the right is a cytosol sample added as a control, containing 40 μg total 
protein. Samples were resolved on 12% SDS-PAGE. 
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Illustration 
 
 
Figure 9 Schematic illustration of significant discoveries established in the present study. 
In the ER, hepatic lipase, which is present in form of inactive, unfolded monomers, forms 
unproductive dimers with nascent ApoA1 molecules. This effectively decreases the rate at which 
hepatocytes are able to secrete ApoA1/HDL, thus causing an unfavorable lipoprotein profile that 
may contribute to the development of atherosclerosis. 
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Discussion 
 
The intentions of the present study were to investigate hepatic lipase complex formation 
along the secretory pathway in hepatocytes; with special attention to interactions with nascent 
high and very low density lipoproteins.  Additionally, the study aimed to determine what 
secretory pathway is responsible for the secretion of properly folded, active, hepatic lipase 
dimers. To determine significant interactions at the ER and cytosol level, co-
immunoprecipitation was used in conjunction with silver staining and western blotting. An in 
vitro budding assay was performed to produce and isolate ER to Golgi transport vesicles, which 
were then analyzed with TCA precipitation and subsequent western blotting. Our data supports a 
model by which inactive hepatic lipase monomers interact with ApoA1 at the ER level, and with 
ApoB100 in the VTVs as an active dimer Figure 9. 
The band at 53kDa in Figure 1 represents hepatic lipase, along with the IgG heavy chain 
at 50kDa. A band is also observable at 28kDa in the boiled as well as the non-boiled samples, 
representing ApoA1. The interaction of these proteins in the ER was confirmed by 
immunoprecipitation experiments, Figure 2. While non-specific binding was observed in our 
IgG control, the signal was significantly more pronounced in our experimental observation using 
anti-HL primary antibodies. Based on the fact that a band is observable at this mass with and 
without boiling in our silver staining experiment indicates that this is a weak interaction, and 
may be unstable under harsh conditions. Namely, the highly reducing environment created by 
buffers used in SDS-PAGE, as well as due to vortexing used to solubilize proteins prior to SDS-
PAGE.  
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To verify the existence of a hetero-dimeric complex of ApoA1 (28 kDa) and hepatic 
lipase (53kDa), further western blot analysis was performed on boiled and non-boiled ER 
samples, both with and without heparin. Based on the presence of bands at approximately 81 
kDa in both non-boiled samples with immunoreactivity to ApoA1 Figure 3a) as well as to 
hepatic lipase Figure 3b), we report that these two proteins interact in the ER of hepatocytes. 
This interaction may explain observations of decreased ApoA1 secretion due to hepatic lipase 
expression, which would confer a pro-atherogenic phenotype in vivo. Interestingly, the inclusion 
of heparin did not produce marked changes in the association of these two proteins. This may be 
attributed to insufficient binding of heparin to the appropriate domains of hepatic lipase, or to a 
lack of appreciable impact of this association on ApoA1 binding at this level. 
It has been demonstrated previously that hepatic lipase and ApoB100 interact in the 
extracellular fluid in vivo [16]. In the present study we have demonstrated a specific interaction 
between ApoB100 in the hepatic ER Figure 5, as well as in hepatic cytosol Figure 4. The faint 
band observed at 515 kDa in both ER and cytosol derived immunoprecipitation samples 
indicates specific binding between ApoB100 and hepatic lipase, but not hepatic lipase and 
ApoB48. While both variants are present in the liver of rodents, only the full length ApoB100 is 
produced in human hepatocytes [38].  
The production of VLDL particles depends on the availability of triglycerides, and in 
their absence, ApoB molecules are often degraded [40, 41]. This elevated lipid content causes 
the VTVs budding from the endoplasmic reticulum to have a low density, which is why they are 
present in the lowest density fractions of the continuous sucrose gradient used to resolve our 
budding assay. As previously reported by our lab, the VLDL transport vesicle, which transports 
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VLDL particles from the ER to the cis-Golgi, contains both ApoB100 and ApoAIV, but not 
ApoA1 [42]. Our present study demonstrates the presence of hepatic lipase in the VTV Figure 6 
a), which had not been identified in this vesicle in previous proteomic analyses of the VTV 
conducted by our lab. The identification of hepatic lipase in this transport vesicle explains its 
presence in cytosolic samples in association with ApoB100, as VTVs are present in the cytosol 
when moving between the ER and cis-Golgi.  
This data suggests that an interaction between hepatic lipase and ApoB100 may mediate 
the movement of hepatic lipase from the ER to the cis-Golgi. Further studies should be 
conducted in cell culture to identify what impact this protein has on VLDL maturation, and to 
determine if changes in its expression can alter the rate or volume of VLDL secretion. Based on 
previous reports and what our data has indicated, hepatic lipase gains catalytic activity upon 
dimerization, at which point it is rapidly secreted from the ER; in the VTV [24]. Thus, this could 
represent a significant interaction involving the VLDL molecule within the VTV. Further studies 
should be conducted to determine definitively if hepatic lipase binding significantly alters VLDL 
transport to the cis-Golgi. 
Calnexin is a 90kDa integral membrane chaperone that assists in the proper folding of 
proteins in the endoplasmic reticulum, and it is known to be specifically involved in hepatic 
lipase maturation [24]. Thus, it can be inferred that this protein is responsible for the band at 
90kDa in the boiled sample of Figure 1. The band at 110kDa in the boiled sample may represent 
LRP, due to their previously described association in mediating LDL particle uptake. However, 
due to differences in local environments in the ER and the extracellular fluid, namely the lack of 
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mature glycosaminoglycans, further analysis was performed with immunoprecipitation to assess 
this possibility.  
 Figure 7 demonstrates a specific interaction between hepatic lipase and LRP in rat 
hepatic cytosol. Hepatic lipase is known to bind with LRP in the presence of heparan sulfate 
proteoglycans, which form at the Golgi level [19]. The vesicles in which these proteins are 
transported are present in the cytosol, as they transport their cargo between sub-cellular 
compartments, which is why they are present in discrete amounts. Based on the absence of LRP 
in VTVs Figure 6 b), which contain hepatic lipase, and that fact that heparan sulfate 
proteoglycans mature and are secreted from the Golgi, this interaction between LRP most 
probably occurs in post-Golgi vesicles, bound for delivery to the cell membrane or for 
proteosomal degradation. Further studies should investigate this interaction in the trans-Golgi 
network, and post-Golgi vesicles. Because interaction between these proteins could not be 
confirmed by western blot analysis, the identity of the 110 kDa band in our silver staining 
procedure remains inconclusive, and warrants further investigation.  
 Based on the presence of equal non-specific binding in samples using hepatic lipase and 
IgG primary antibodies Figure 8, this data shows no specific interaction between ApoA4 and 
hepatic lipase in rat hepatic cytosol. Previous reports from in vivo observations have 
demonstrated a lack of physiological impact of exogenous HL administration on serum ApoAIV 
levels [43]. Hepatic lipase is known to interact with ApoA1 and ApoB100 containing particles 
via its bridging function, but not to ApoAIV containing particles. Taken with our data 
demonstrating interactions between hepatic lipase, ApoB100, LRP, and ApoA1, it can be stated 
with confidence that undescribed intricacies to the function of hepatic lipase exist, and that they 
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are mediated by direct interaction with lipoproteins and lipoprotein receptors along the secretory 
pathway. 
Conclusion and Future Directions 
 
The identification of a direct interaction between hepatic lipase and ApoA1 at the ER 
level, as well as the existence of an 81 kDa complex with immunoreactivity to both proteins in 
this same compartment, strongly suggests that direct binding of hepatic lipase to ApoA1 plays a 
role in diminishing the ability of hepatocytes to secrete HDL. Furthermore, the identification of 
direct interaction between hepatic lipase and ApoB100 in both the ER and in the VTV suggests 
that this protein’s secretion is co-regulated with VLDL secretion. This interaction may also 
mediate degradation by a yet described pathway involving LRP at the Golgi level.  
Based on the presented data and its interpretation, future studies should be aimed at 
determining the impact of varying levels of hepatic lipase expression on VTV formation, as well 
as its impact on the mechanisms responsible for movement of HDL particles from the 
endoplasmic reticulum, which is not well characterized in and of itself. The point along the 
secretory pathway at which lipidation of VLDL particles is complete is still a subject of debate. 
Taken with the fact that movement between the ER and cis-Golgi in the VTV is the rate limiting 
step in VLDL secretion, the discovery that this vesicle contains hepatic lipase after the enzyme 
forms an active dimer is of particular interest. Thus, attention should be given to determining 
what impact is elicited by the presence of dimeric hepatic lipase within the VTV. The 
significance of the described interaction between hepatic lipase and LRP in the ER and post-
Golgi vesicles should also be investigated. Previous studies have described mechanisms by 
32 
 
which the LDL receptor facilitates degradation of ApoB containing particles at the Golgi level 
[44], thus it is not farfetched to suggest that the interaction between hepatic lipase and LRP may 
facilitate a similar process.  
  
33 
 
Works Cited 
 
1. Hahn, P.F., Abolishment of Alimentary Lipemia Following Injection of Heparin. Science, 
1943. 98(2531): p. 19-20. 
2. Sniderman, A.D., et al., Evidence for the hepatic origin of a canine post-heparin plasma 
triglyceride lipase. FEBS Lett, 1974. 42(2): p. 157-60. 
3. Augustin, J., et al., A comparison of molecular properties of hepatic triglyceride lipase 
and lipoprotein lipase from human post-heparin plasma. J Biol Chem, 1978. 253(9): p. 
2912-20. 
4. Ostlund-Lindqvist, A.M., Properties of salt-resistant lipase and lipoprotein lipase 
purified from human post-heparin plasma. Biochem J, 1979. 179(3): p. 555-9. 
5. Kuusi, T., et al., Postheparin plasma lipoprotein and hepatic lipase are determinants of 
hypo- and hyperalphalipoproteinemia. J Lipid Res, 1989. 30(8): p. 1117-26. 
6. Gonzalez-Navarro, H., et al., Identification of mouse and human macrophages as a site of 
synthesis of hepatic lipase. J Lipid Res, 2002. 43(5): p. 671-5. 
7. Zambon, A., et al., In vivo evidence of a role for hepatic lipase in human apoB-
containing lipoprotein metabolism, independent of its lipolytic activity. J Lipid Res, 2000. 
41(12): p. 2094-9. 
8. Ramsamy, T.A., et al., HDL regulates the displacement of hepatic lipase from cell 
surface proteoglycans and the hydrolysis of VLDL triacylglycerol. J Lipid Res, 2003. 
44(4): p. 733-41. 
9. Kuusi, T., et al., Localization of the heparin-releasable lipase in situ in the rat liver. 
Biochem J, 1979. 181(1): p. 245-6. 
10. Connelly, P.W. and R.A. Hegele, Hepatic lipase deficiency. Crit Rev Clin Lab Sci, 1998. 
35(6): p. 547-72. 
11. Rashid, S., et al., Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic 
states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase 
activity. Clin Biochem, 2003. 36(6): p. 421-9. 
12. Hirayama, S. and T. Miida, Small dense LDL: An emerging risk factor for cardiovascular 
disease. Clin Chim Acta, 2012. 414: p. 215-24. 
13. Choi, S.H. and H.N. Ginsberg, Increased very low density lipoprotein (VLDL) secretion, 
hepatic steatosis, and insulin resistance. Trends Endocrinol Metab, 2011. 22(9): p. 353-
63. 
14. Lambert, G., et al., Hepatic lipase deficiency decreases the selective uptake of HDL-
cholesteryl esters in vivo. J Lipid Res, 2000. 41(5): p. 667-72. 
15. Castelli, W.P., et al., Incidence of coronary heart disease and lipoprotein cholesterol 
levels. The Framingham Study. JAMA, 1986. 256(20): p. 2835-8. 
16. Choi, S.Y., et al., Interaction between ApoB and hepatic lipase mediates the uptake of 
ApoB-containing lipoproteins. J Biol Chem, 1998. 273(32): p. 20456-62. 
17. Ji, Z.S., et al., Heparan sulfate proteoglycans participate in hepatic lipaseand 
apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high 
density lipoproteins. J Biol Chem, 1997. 272(50): p. 31285-92. 
34 
 
18. Verges, M., et al., Endocytosis of hepatic lipase and lipoprotein lipase into rat liver 
hepatocytes in vivo is mediated by the low density lipoprotein receptor-related protein. J 
Biol Chem, 2004. 279(10): p. 9030-6. 
19. Kounnas, M.Z., et al., The cellular internalization and degradation of hepatic lipase is 
mediated by low density lipoprotein receptor-related protein and requires cell surface 
proteoglycans. J Biol Chem, 1995. 270(16): p. 9307-12. 
20. Perret, B., et al., Hepatic lipase: structure/function relationship, synthesis, and 
regulation. J Lipid Res, 2002. 43(8): p. 1163-9. 
21. Marques-Vidal, P., et al., Hepatic lipase promotes the uptake of HDL esterified 
cholesterol by the perfused rat liver: a study using reconstituted HDL particles of defined 
phospholipid composition. J Lipid Res, 1994. 35(3): p. 373-84. 
22. Wade, R.L., et al., Hepatic lipase deficiency attenuates mouse ovarian progesterone 
production leading to decreased ovulation and reduced litter size. Biol Reprod, 2002. 
66(4): p. 1076-82. 
23. Doolittle, M.H., et al., Hepatic lipase maturation: a partial proteome of interacting 
factors. J Lipid Res, 2009. 50(6): p. 1173-84. 
24. Ben-Zeev, O. and M.H. Doolittle, Maturation of hepatic lipase. Formation of functional 
enzyme in the endoplasmic reticulum is the rate-limiting step in its secretion. J Biol 
Chem, 2004. 279(7): p. 6171-81. 
25. Gonzalez-Navarro, H., et al., The ligand-binding function of hepatic lipase modulates the 
development of atherosclerosis in transgenic mice. J Biol Chem, 2004. 279(44): p. 
45312-21. 
26. Dichek, H.L., K. Qian, and N. Agrawal, Divergent effects of the catalytic and bridging 
functions of hepatic lipase on atherosclerosis. Arterioscler Thromb Vasc Biol, 2004. 
24(9): p. 1696-702. 
27. Nong, Z., et al., Hepatic lipase expression in macrophages contributes to atherosclerosis 
in apoE-deficient and LCAT-transgenic mice. J Clin Invest, 2003. 112(3): p. 367-78. 
28. Escola-Gil, J.C., et al., Hepatic lipase- and endothelial lipase-deficiency in mice 
promotes macrophage-to-feces RCT and HDL antioxidant properties. Biochim Biophys 
Acta, 2013. 1831(4): p. 691-7. 
29. Getz, G.S. and C.A. Reardon, The mutual interplay of lipid metabolism and the cells of 
the immune system in relation to atherosclerosis. Clin Lipidol, 2014. 9(6): p. 657-671. 
30. Chiu, H.K., et al., Mice lacking hepatic lipase are lean and protected against diet-
induced obesity and hepatic steatosis. Endocrinology, 2010. 151(3): p. 993-1001. 
31. Minehira, K., et al., Blocking VLDL secretion causes hepatic steatosis but does not affect 
peripheral lipid stores or insulin sensitivity in mice. J Lipid Res, 2008. 49(9): p. 2038-44. 
32. Brown, J.D., et al., VLDL hydrolysis by hepatic lipase regulates PPARdelta 
transcriptional responses. PLoS One, 2011. 6(7): p. e21209. 
33. Bamji-Mirza, M., W. Zhang, and Z. Yao, Expression of human hepatic lipase negatively 
impacts apolipoprotein A-I production in primary hepatocytes from Lipc-null mice. J 
Biomed Res, 2014. 28(3): p. 201-12. 
34. Erickson, B., et al., Endoplasmic reticulum-localized hepatic lipase decreases 
triacylglycerol storage and VLDL secretion. Biochim Biophys Acta, 2013. 1831(6): p. 
1113-23. 
35 
 
35. Siddiqi, S.A., VLDL exits from the endoplasmic reticulum in a specialized vesicle, the 
VLDL transport vesicle, in rat primary hepatocytes. Biochem J, 2008. 413(2): p. 333-42. 
36. Tiwari, S., S. Siddiqi, and S.A. Siddiqi, CideB protein is required for the biogenesis of 
very low density lipoprotein (VLDL) transport vesicle. J Biol Chem, 2013. 288(7): p. 
5157-65. 
37. Brown, R.J., et al., Severe hypoalphalipoproteinemia in mice expressing human hepatic 
lipase deficient in binding to heparan sulfate proteoglycan. J Biol Chem, 2004. 279(41): 
p. 42403-9. 
38. Tennyson, G.E., et al., Expression of apolipoprotein B mRNAs encoding higher- and 
lower-molecular weight isoproteins in rat liver and intestine. Proc Natl Acad Sci U S A, 
1989. 86(2): p. 500-4. 
39. Barlowe, C., COPII and selective export from the endoplasmic reticulum. Biochim 
Biophys Acta, 1998. 1404(1-2): p. 67-76. 
40. Yao, Z., K. Tran, and R.S. McLeod, Intracellular degradation of newly synthesized 
apolipoprotein B. J Lipid Res, 1997. 38(10): p. 1937-53. 
41. Yao, Z. and R.S. McLeod, Synthesis and secretion of hepatic apolipoprotein B-
containing lipoproteins. Biochim Biophys Acta, 1994. 1212(2): p. 152-66. 
42. Rahim, A., et al., Proteomic analysis of the very low density lipoprotein (VLDL) 
transport vesicles. J Proteomics, 2012. 75(7): p. 2225-35. 
43. Braschi, S., et al., Hepatic lipase affects both HDL and ApoB-containing lipoprotein 
levels in the mouse. Biochim Biophys Acta, 1998. 1392(2-3): p. 276-90. 
44. Twisk, J., et al., The role of the LDL receptor in apolipoprotein B secretion. J Clin Invest, 
2000. 105(4): p. 521-32. 
 
